The Efficacy of CILostazol ON Ischemic Complications After DES Implantation

Overview

Objectives : * To evaluate the influence of concomitant use of cilostazol with aspirin and clopidogrel on the composite cardiovascular adverse outcomes (cardiac death, myocardial infarction, nonhemorrhagic stroke, target lesion revascularization) after drug-eluting stent implantation Study Design : Prospective, open label, two arm, randomized multicenter trial to test the superiority of cilostazol group compared with the control group. Patients will be randomized according to the use of cilostazol Patient Enrollment: 960 patients enrolled at 5 centers in Korea Patient Follow-up : Clinical follow-up will occur at 1, 3 and 6 months. Angiographic follow-up will be recommended to all patient at 6 months after index procedure. Primary Endpoint * Composite of adverse cardiovascular/cerebrovascular outcomes (cardiac death, myocardial infarction, nonhemorrhagic stroke, target lesion revascularization) within 6 months Secondary Endpoint * All cause of death, stent thrombosis, and each component of primary endpoint at six months * PRU level measured at discharge after the index procedure and after six months Safety Endpoint * Bleeding complications according to TIMI criteria * The incidence of drug discontinuation * Heart rate

Stratified randomization by statin type (rosuvastatin or atorvastatin) and the center was performed

Conditions